Immunomodulatory and neuroprotective effects of inosine

被引:249
作者
Haskó, G
Sitkovsky, MV
Szabó, C
机构
[1] Inotek Pharmaceut Corp, Beverly, MA 01915 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA
[3] Hungarian Acad Sci, Inst Expt Med, Dept Pharmacol, H-1450 Budapest, Hungary
[4] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA
[5] Semmelweis Univ, Sch Med, Inst Human Physiol & Clin Expt Res, H-1082 Budapest, Hungary
关键词
D O I
10.1016/j.tips.2004.01.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine has been considered as a potential immunomodulatory and neuroprotective agent for 30 years. Inosine, a major degradation product of adenosine, was thought originally to have no biological effects. However, recent studies demonstrate that inosine has potent immunomodulatory and neuroprotective effects. Inosine enhances mast-cell degranulation, attenuates the production of pro-inflammatory mediators by macrophages, lymphocytes and neutrophils, and is protective in animal models of sepsis, ischemia-reperfusion and autoimmunity. Inosine preserves the viability of glial cells and neuronal cells during hypoxia, and stimulates axonal regrowth after injury. The biological actions of inosine might involve effects on adenosine receptors, poly(ADP-ribose) polymerase and cellular energy levels. In this article, we review recent observations indicating that it might be possible to exploit inosine therapeutically for the treatment of tissue damage caused by inflammation and ischemia.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 65 条
[51]  
SEEKAMP A, 1993, AM J PATHOL, V143, P453
[52]   Quality-of-service support for multimedia applications [J].
Shepherd, D ;
Scott, A ;
Rodden, T .
IEEE MULTIMEDIA, 1996, 3 (03) :78-82
[53]   Use of the A2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo [J].
Sitkovsky, MV .
BIOCHEMICAL PHARMACOLOGY, 2003, 65 (04) :493-501
[54]   Inosine improves gut permeability and vascular reactivity in endotoxic shock [J].
Soriano, FG ;
Liaudet, L ;
Marton, A ;
Haskó, G ;
Lorigados, CB ;
Deitch, EA ;
Szabó, C .
CRITICAL CARE MEDICINE, 2001, 29 (04) :703-708
[55]   Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease [J].
Spitsin, S ;
Hooper, DC ;
Leist, T ;
Streletz, LJ ;
Mikheeva, T ;
Koprowski, H .
MULTIPLE SCLEROSIS, 2001, 7 (05) :313-319
[56]  
Stone TW, 2002, ADV EXP MED BIOL, V513, P249
[57]   Suppression of macrophage in inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists [J].
Szabó, C ;
Scott, GS ;
Virág, L ;
Egnaczyk, G ;
Salzman, AL ;
Shanley, TP ;
Haskó, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (02) :379-387
[58]   Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells [J].
Tilley, SL ;
Wagoner, VA ;
Salvatore, CA ;
Jacobson, MA ;
Koller, BH .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (03) :361-367
[59]   New therapeutic targets revealed through investigations of innate immunity [J].
Ulevitch, RJ .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S8-S12
[60]   Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death [J].
Virág, L ;
Szabó, C .
FASEB JOURNAL, 2001, 15 (01) :99-107